Publications by authors named "Mitchell N Davis"

Claim this Profile
D
Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection.
Tarik Asselah, Stephen D Shafran, Stefan Bourgeois, Ching-Lung Lai, Philippe Mathurin, Mitchell N Davis

J Viral Hepat· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
Edward J Gane, Mitchell L Shiffman, Kyle Etzkorn, Giuseppe Morelli, Catherine A M Stedman, Mitchell N Davis

Hepatology· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.
Gregory T Everson, William J Towner, Mitchell N Davis, David L Wyles, Ronald G Nahass

Ann Intern Med· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.
Michael P Manns, Jonathan McCone, Mitchell N Davis, Lorenzo Rossaro, Eugene Schiff

Liver Int· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.
Robert A Ogert, John A Howe, John M Vierling, Paul Y Kwo, Eric J Lawitz, Mitchell N Davis

Antivir Ther· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
Kris V Kowdley, Eric Lawitz, Israel Crespo, Tarek Hassanein, Mitchell N Davis

Lancet· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir for previously untreated chronic hepatitis C infection.
Eric Lawitz, Alessandra Mangia, David Wyles, Maribel Rodriguez-Torres, Tarek Hassanein, Mitchell N Davis

N Engl J Med· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
Paul Y Kwo, Eric J Lawitz, Jonathan McCone, Eugene R Schiff, John M Vierling, Mitchell N Davis

Lancet· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
John G McHutchison, Eric J Lawitz, Mitchell L Shiffman, Andrew J Muir, Greg W Galler, Mitchell N Davis

N Engl J Med· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis